N-3 PUFAs and their specialized pro-resolving lipid mediators on airway inflammatory response: beneficial effects in the prevention and treatment of respiratory diseases

dc.contributor.authorZúñiga-Hernández, Jessica
dc.contributor.authorSambra, Verónica
dc.contributor.authorEcheverría González, Francisca Cecilia
dc.contributor.authorVidela, Luis A.
dc.contributor.authorValenzuela, Rodrigo
dc.date.accessioned2022-12-28T12:55:15Z
dc.date.available2022-12-28T12:55:15Z
dc.date.issued2022
dc.description.abstractRespiratory diseases include a wide range of pathologies with different clinical manifestations, affecting the normal airways and lung function. An increase in the inflammatory response is considered a characteristic hallmark of these diseases, being also a critical factor for their progression. The n-3 polyunsaturated fatty acids (n-3 PUFAs) eicosapentaenoic acid (C20:4n-3, EPA), docosahexaenoic acid (C22:6n-3, DHA) and their lipid mediators are known to have an inflammation pro-resolution effect. The effects of these n-3 PUFAs in the prevention and treatment of respiratory diseases are beginning to be understood. Consequently, this article aims to analyze the influence of n-3 PUFAs and their lipid mediators on the inflammatory response in respiratory health, emphasizing recent data concerning their beneficial effects in the prevention and possible treatment of different respiratory diseases, particularly asthma, airway allergic syndromes and chronic obstructive pulmonary disease. The review includes studies regarding the effects of EPA, DHA, and their specialized pro-resolving lipid mediators (SPMs) on in vivo and in vitro models of respiratory disease, concluding that EPA and DHA have a positive impact in attenuating the pro-inflammatory response in respiratory diseases, reducing symptoms like nasal congestion, fever and difficulty in breathing. Controversial data reported are probably due to differences in several factors, including the dosages, administration vehicles, and the supplementation times employed, which are aspects that remain to be addressed in future studies.
dc.fechaingreso.objetodigital2022-12-28
dc.fuente.origenSIPA
dc.identifier.doi10.1039/D1FO03551G
dc.identifier.eissn2042-650X
dc.identifier.urihttps://pubs.rsc.org/en/content/articlelanding/2022/FO/D1FO03551G
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/66143
dc.information.autorucDepartamento de ciencias de la salud ; Echeverría González, Francisca Cecilia ; 0000-0002-9661-0377 ; 1232657
dc.issue.numero8
dc.language.isoen
dc.nota.accesoContenido parcial
dc.pagina.final4272
dc.pagina.inicio4260
dc.revistaFood & Function
dc.rightsacceso restringido
dc.subject.ods03 Good health and well-being
dc.subject.odspa03 Salud y bienestar
dc.titleN-3 PUFAs and their specialized pro-resolving lipid mediators on airway inflammatory response: beneficial effects in the prevention and treatment of respiratory diseases
dc.typeartículo
dc.volumen13
sipa.codpersvinculados1232657
sipa.indexWOS
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
N3 PUFAs and their specialized pro-resolving lipid mediators on airway inflammatory response, beneficial effects in the prevention and treatment of respiratory diseases.pdf
Size:
108.1 KB
Format:
Adobe Portable Document Format
Description: